Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
1.30
Nov 05 • 3:59 PM ET Dollar change-0.05 Percentage change(-3.35%)
Aftermarket Close
1.34
Aftermarket • 7:37 PM ET Dollar change+0.04 Percentage change(3.08%)
Index
-
Market Cap
8.87M
Enterprise Value
-0.55M
Income
-21.24M
Sales
0.00M
Book/sh
0.90
Cash/sh
2.73
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
16
IPO
Sep 25, 2020
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
1.45
P/C
0.48
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
5.58
Current Ratio
5.58
Debt/Eq
1.67
LT Debt/Eq
1.67
Option/Short
No / Yes
EPS (ttm)
-6.79
EPS next Y
-5.30
EPS next Q
-1.27
EPS this Y
69.37%
EPS next Y
-75.69%
EPS next 5Y
36.90%
EPS past 3/5Y
89.18% 38.92%
Sales past 3/5Y
- -
EPS Y/Y TTM
15.38%
Sales Y/Y TTM
-
EPS Q/Q
-12.66%
Sales Q/Q
-
Insider Own
39.39%
Insider Trans
10.20%
Inst Own
34.24%
Inst Trans
22.62%
ROA
-110.10%
ROE
-365.70%
ROIC
-144.36%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
2.38%
SMA50
-20.66%
SMA200
-63.01%
Trades
Shs Outstand
6.15M
Shs Float
4.14M
52W High
36.00 -96.39%
52W Low
1.00 30.00%
Volatility
19.64% 14.92%
ATR (14)
0.20
RSI (14)
43.39
Beta
0.78
Rel Volume
0.30
Avg Volume
81.62K
Volume
24,298
Perf Week
-25.71%
Perf Month
-12.16%
Perf Quarter
-62.18%
Perf Half Y
-59.08%
Perf YTD
-96.05%
Perf Year
-91.25%
Perf 3Y
-90.88%
Perf 5Y
-99.43%
Perf 10Y
-
Prev Close
1.35
Price
1.30
Change %
-3.35%
Consensus
Buy
Avg. Price Target
$37.50
Implied Upside
+2,784.6%
Analysts2incl. previous ratings
Rating Distribution1 Buy · 1 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Aug 20, 2026Initiated
GGuggenheim
Buy$9+592.3%
Jan 29, 2026Downgrade
HH.C. Wainwright
Buy → Neutral
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Middleton Fred ADirectorJun 25 '26Buy0.80248,972199,9991,063,272Jun 29 08:45 AM
CalciMedica, Inc. is a clinical-stage biopharmaceutical company, which engages in developing therapies for life-threatening inflammatory diseases. The firm's product candidate, Auxora, helps in treating acute pancreatitis and asparaginase-associated pancreatitis. The company was founded by Kenneth A. Stauderman and Gonul Velicelebi in 2007 and is headquartered in La Jolla, CA.
CEO & DirectorDr. A. Rachel Leheny Ph.D.
Chief Business Officer & Vice Chairman of the BoardMr. Eric W. Roberts
Chief Medical OfficerDr. Sudarshan Hebbar M.D.
M.B.A.Mr. Michael J. Dunn B.A.
Co-Founder and Scientific AdvisorDr. Anjana Rao Ph.D.